Oncology Total Current Liabilities from 2010 to 2025
| TOI Stock | USD 1.11 0.10 8.26% |
Total Current Liabilities | First Reported 2020-03-31 | Previous Quarter 46.8 M | Current Value 52.2 M | Quarterly Volatility 16.8 M |
Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 4.3 M or Interest Expense of 7.9 M, as well as many indicators such as Price To Sales Ratio of 0.056, Dividend Yield of 0.0235 or PTB Ratio of 9.86. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
Oncology | Total Current Liabilities |
Latest Oncology Institute's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Oncology Institute over the last few years. Total Current Liabilities is an item on Oncology Institute balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Oncology Institute are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Oncology Institute's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Oncology Total Current Liabilities Regression Statistics
| Arithmetic Mean | 21,608,574 | |
| Geometric Mean | 19,205,916 | |
| Coefficient Of Variation | 54.85 | |
| Mean Deviation | 10,028,904 | |
| Median | 13,585,451 | |
| Standard Deviation | 11,853,308 | |
| Sample Variance | 140.5T | |
| Range | 38.6M | |
| R-Value | 0.82 | |
| Mean Square Error | 49.6T | |
| R-Squared | 0.67 | |
| Significance | 0.0001 | |
| Slope | 2,038,177 | |
| Total Sum of Squares | 2107.5T |
Oncology Total Current Liabilities History
About Oncology Institute Financial Statements
Investors use fundamental indicators, such as Oncology Institute's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Oncology Institute's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 52.2 M | 34.6 M |
Currently Active Assets on Macroaxis
When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:Check out the analysis of Oncology Institute Correlation against competitors. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.71) | Revenue Per Share | Quarterly Revenue Growth 0.169 | Return On Assets | Return On Equity |
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.